Up to two research calls per year
Research grants
Currently, the majority of our funding is awarded via research grants to academic institutions, although consortia including industry are welcome to apply.
Usually, two scheduled calls for research proposals are held each year. They can either be ‘All priorities’ calls which means that project topics should fit within one or more of EB Resnet’s four strategic research priorities. Alternatively, a scheduled ‘Special’ call may be issued to invite proposals to address identified important unmet research questions, technology needs or clinical consequences arising from EB (e.g. chronic inflammation and fibrosis).
Project scope 'Research grants'
- Fundamental to preclinical research, and clinical trials projects in EB
- Research projects must fall into the scope of a current research call: either an 'All priorities' call or a 'Special call' i.e. chronic inflammation and fibrosis
- Lead applicant: researchers and/or clinicians (cooperation with industry welcome and possible)
- Project duration: 6 to 36 months
- Funding: up to EUR 90,000.00 p.a.
The essential purpose of the grant is to support a single research project in the field of Epidermolysis Bullosa (EB acquisita is excluded) – a piece of work designed to answer a single question or a small group of related questions.
Closed Calls 2022
This year's All Priorities Call closed on 06 September 2022. Full details including deadlines and scope are displayed under Closed Call 'AP Call 2022'.
In addition, a Special Ad-hoc Call 2022 focussing on Proof-of-Concept Proposals on Drug Repurposing for EB closed on 06 September 2022 too. Full details including deadlines and scope are displayed under Closed Call 'Special Ad-hoc Call 2022'.
The results of the All Priorities Call 2021 can be found in the overview table for 2021.
Funded projects (EB Resnet & DEBRA International research calls)
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| All Priorities 2021 | Dr Carlos León | University Carlos III de Madrid, Spain | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria, DEBRA Sweden, EB-Loppet |
| All Priorities 2021 | Dr Zlatko Kopecki | University of South Australia, Australia | 2 years & 3 months | Symptom prevention & relief | All types | DEBRA Austria |
| All Priorities 2021 | Prof Thomas Magin | University of Leipzig, Germany | 3 years | Molecular therapy, Cellular therapy | Simplex | DEBRA Austria |
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| All Priorities 2020 | Prof Alain Hovnanian | INSERM, Paris, France | 1 year | Molecular therapy, Cellular therapy | Dystrophic | DEBRA France |
| All Priorities 2020 | Dr Nicholas Veldhuis | Monash Institute of Pharmaceutical Sciences, Monash University, Australia | 3 years | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| All Priorities 2020 | Prof Eli Sprecher | Tel Aviv Sourasky Medical Center, Israel | 3 years | EB genetics, epigenetics & biology | all types | DEBRA Austria |
All Priorities 2020
| Dr Ignacia Fuentes | Clínica Alemana-Universidad del Desarrollo, Chile | 1,5 years | Cellular therapy, Symptom prevention & relief | all types | DEBRA France & DEBRA Austria |
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| All Priorities 2019 | Prof Valerie Brunton | University of Edinburgh, UK | 2 years | Skin cancer & fibrosis | Kindler | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof Karine Raymond | Leiden University Medical Center, The Netherlands | 3 years | EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
| All Priorities 2019 | Dr Colin Butler | University College London, Great Ormond Street Institute of Child Health, UK | 2 years | Symptom prevention & relief | Junctional | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof. Liam Grover | University of Birmingham, UK | 2 years | Skin cancer & fibrosis | Dystrophic | DEBRA UK DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2018 | Prof Jouni Uitto | Thomas Jefferson University, Philadelphia USA | 2 years | EB genetics, epigenetics & biology | Dystrophic Junctional Simplex | DEBRA Austria |
All Priorities Call 2018 | Prof Ganna Bilousova | University of Colorado, USA | 3 years | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2018 | Dr Su Lwin | Kings College London, UK | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA UK |
All Priorities Call 2018 | Prof Gareth Inman | University of Glasgow | 1 year | Skin cancer & fibrosis | Dystrophic | DEBRA UK |
| CIF Call 2018 | Prof Giovanna Zambruno | Bambino Gesu Ospedale, Italy | 3 years | Skin cancer & fibrosis, EB genetics, epigenetics & biology | Dystrophic
| DEBRA Austria DEBRA UK DEBRA Spain |
| CIF Call 2018 | Prof Ulrich Rodeck taken over by Prof. Andy South | Thomas Jefferson University, USA | 2 years | Symptom prevention & relief | Dystrophic | DEBRA Austria DEBRA Ireland |
| CIF Call 2018 | Dr Yanling Liao | New York Medical College, USA | 3 years | Symptom prevention & relief, Immunology | Dystrophic | DEBRA UK DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2017 | Prof Cristina Has | University of Freiburg, Germany | 1 year | EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
All Priorities Call 2017 | Dr Antonia Reimer | University of Freiburg, Germany | 3 years | EB genetics, epigenetics & biology | Dystrophic Junctional | DEBRA Austria |
Innovative Research Grant Call 2017 | Prof Margarita Calvo | Pontificia Universidad Católica de Chile, Chile | 1,5 years | Symptom prevention & relief | Dystrophic | DEBRA Austria
|
Innovative Research Grant Call 2017 | Dr Cédric Gaggioli | Association pour le Développement des Sciences Médicales, Faculté de Médicine, France | 1 year | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2017 | Prof Daniele Castiglia | IRCCS, Rome, Italy | 3 years | Skin cancer & fibrosis, EB genetics, epigenetics & biology | Dystrophic | DEBRA Austria DEBRA UK |
All Priorities Call 2017 | Prof Thomas Magin | University of Leipzig, Germany | 3 years | Molecular therapy, EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
All Priorities Call 2017 | Prof Alain Hovnanian | INSERM, Departement of Genetics, France | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
Wound Healing Call 2017 | Initiated by Professor Marcel Jonkman, Nicholas Schräder, and Professor André P Wolff | University Medical Center Groningen | 3 years | Symptom prevention & relief | all types | DEBRA UK |
Wound Healing Call 2017 | Prof Dr Sabine Eming | University Hospital of Cologne, Germany | 3 years | Symptom prevention & relief | Dystrophic | DEBRA UK, DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2016 | Dr Fernando Larcher | CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas Prospósito, SPAIN | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof Arnoud Sonnenberg | Netherlands Cancer Institute, THE NETHERLANDS | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof Jouni Uitto | Thomas Jefferson University, Philadelphia, USA | 2 years | EB genetics, epigenetics & biology | Simplex Dystrophic Junctional |
DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2015 | Dr Andrew South | Thomas Jefferson University, Philardelphia, USA | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2015 | Dr Marius Wernig | Standord University, California, USA | 3 years | Molecular therapy | Dystrophic | DEBRA Austria |
Clinical Call 2015 | Prof Leena Bruckner- Tuderman | University of Freiburg Medical Center, Departement of Determatology, GERMANY | 4 years | Symptom prevention & relief, Clinical trial Phase II | Dystrophic | DEBRA Austria |
Clinical Call 2015 | Dr Andrew South, Prof Johann Bauer, Prof Jemima Mellerio | Thomas Jefferson University, Philadelphia, US, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK | Start date 1.4.2017 | Skin cancer & fibrosis, Clinical trail Phase II | Dystrophic | DEBRA UK |
Clinical Call 2015 | Prof Peter Marinkovich | Stanford University, USA | 3 years | Skin cancer & fibrosis, Molecular therapy Clinical trial Phase II | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2014-06 | Dr Jouni Uitto | Dermatology and Cutaneous Biology, Philardelphia, USA | 3 years | EB genetics, epigenetics & biology | Dystrophic | DEBRA UK |
All Priorities Call 2014-06 | Dr John McGrath | St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK | 2 years | Cellular therapy | Dystrophic | Cure EB (former Sohana Reserach Fund) |
All Priorities Call 2014-06 | Dr Gareth Inman, Dr Andy South | University of Dundee, Division of Cancer Research, Medical Research Institute, College of Medicine Dentistry and Nursing, UK | 3 years | Skin cancer & fibrosis | Dystrophic | DEBRA UK |
All Priorities Call 2014-06 | Prof Valerie Brunton | University of Edingburgh, UK | 3 years | EB genetics, epigenetics & biology | Kindler | DEBRA UK |
All Priorities Call 2014-06 | Prof Mitchell Cairo | New York Medical College, New York, USA | 2 years (+ 1) | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2014-06 | Dr Verena Wally (Ext. Bauer) | EB House Austria, Paracelsus Private Medical University Salzburg, Austria | 1 year | Molecular therapy, Cellular therapy | Simplex | DEBRA Austria |
All Priorities Call 2014-06 | Prof Crstina Has | University of Freiburg Medical Center, Departement of Dermatology, GERMANY | 2 years | EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
All Priorities Call 2014-12 | Dr Mark Saville | Ninewells Hospital and Medical School, University of Dundee, UK | 3 years | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2014-12 | Prof Leena Bruckner-Tuderman | University of Freiburg Medical Center, Germany | Extension | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2013-06 | Dr Andrew South | Wellcome Trust Centre for Molecular Medicine, Clinical Research Centre, University of Dundee, UK | 2 years | Skin cancer & fibrosis | Dystrophic | DEBRA UK |
All Priorities Call 2013-06 | Dr Cedric Gaggioli | IRCAN - Institute for Research on Cancer and Aging, Nice, France | 40 months | Skin cancer & fibrosis | Dystrophic | DEBRA UK |
All Priorities Call 2013-06 | Dr Derry Roopenian | The Jackson Laboratory, USA | 3 years | EB genetics, epigenetics & biology | Junctional | DEBRA UK |
All Priorities Call 2013-06 | Dr Iris Gratz | University of Salzburg, Departement of Molecular Biology, Austria | 2 years | Molecular therapy, Cellular therapy, Immunology | Dystrophic | DEBRA Austria |
All Priorities Call 2013-06 | Prof John McGrath | King’s College London, UK | Extension | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
AP Call 2012-11 | Prof Edel O'Toole | Centre for Cutaneous Research, Blizard Institute, London, UK | 1 year | Skin cancer & fibrosis | Dystrophic | DEBRA UK |
AP Call 2012-11 | Prof Johan Bauer | Division of Molecular Dermatology and EB House Austria, Paracelsus Private Medical University Salzburg, Austria | 3 years | Molecular therapy, Cellular therapy | Junctional | DEBRA UK |
3MEuro Call 2012 | Prof Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Determatology, Germany | 2 years | Cellular therapy | Dystrophic | DEBRA Austria |
3MEuro Call 2012 | Prof Ellen Brigitte Lane | IMB - Institute of Medical Biology, Singapure | 2 years | Molecular therapy | Simplex, Dowling Meara | DEBRA Austria |
3MEuro Call 2012 | Prof Peter Marinkovich | Stanford University, California, USA | 3 years | Molecular therapy, Cellular therapy | Dystrophic |
DEBRA Austria |
3MEuro Call 2012 | Dr Waseem Qasim | Molecular Immunology Unit UCL Institute of Child Health, London, UK | 3 years | Molecular therapy | Dystrophic | DEBRA Austria |
3MEuro Call 2012 | Prof Dennis Roop | University of Colorade, Denver, USA | 3 years | Cellular therapy | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2011 | Prof Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Dermatology, GERMANY | 3 years + 1 year | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2011 | Prof Johann Bauer | PMU, Salzburg, AUSTRIA | 3 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2011 | Prof Mitchell Cairo | New York Medical College, New York, USA | 2 years + 1 year | Molecular therapy, Cellular therapy | Dystrophic |
DEBRA Austria |
All Priorities Call 2011 | Prof Ellen Brigitte Lane | IMB - Institute of Medical Biology, SINGAPORE | 3 years | Molecular therapy | Simplex | DEBRA Austria |
All Priorities Call 2011 | Dr Derry Charles Roopenian | The Jackson Laboratory, Bar Harbor, Main, USA | 1 year | EB genetics, epigenetics & biology | Junctional | DEBRA Austria |
All Priorities Call 2011-06 | Prof Irwin McLean, Prof John McGrath | University of Dundee, UK | 1 year | Molecular therapies | DEBRA UK | |
All Priorities Call 2011-06 | Prof Johan McGrath | Guy's and St Thomas NHS Foundation Trust, UK | 2,5 years | Molecular therapy | all types | DEBRA UK |
All Priorities Call 2011-06 | Arnoud Sonnenberg | The Netherlands Cancer Institute (NKI), The Netherlands | 2 years | Cellular therapy | Kindler | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2010-12 | Prof Giovanna Zambruno | Laboratory and Cell Biology, Instituto Dermopatico dell'Immacolata, Rome, Italy | 2 years | Symptom prevention & relief | Dystrophic | DEBRA UK |
All Priorities Call 2010-12 | Prof Mc Lean | University of Dundee, Division of Molecular Medicine, Epithelial Genetics Groupe UK | 3 years | Cellular therapy | Simplex | DEBRA UK |
All Priorities Call 2010-06 | Dr Alessandra Recchia | Centre fro regenerative Medicine, University of Modena and Reggio Emilia, ITALY | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2010-06 | Prof Edel Ann O’Toole | Queen Mary University of London, Centre for Cell Biology and Cutaneous Research UK | 4,5 years | Cellular therapy | Dystrophic | DEBRA UK |
All Priorities Call 2010-01 | Dr Cedric Gaggioli | A.D.S.M. Association pour le Développment des Sciences Médicales, Faculté de Médicine, Nice, FRANCE | 1 year | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2010-01 | Prof John McGrath | King's College London, School of Medicine, St. John's Institute of Dermatology, UK | 2 years + 9 months | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2010-01 | Prof Dennis Roop | University of Colorado, Denver, USA | 2 years | Cellular therapy | Simplex |
DEBRA Austria |
All Priorities Call 2010-01 | Prof John Sundberg | The Jackson Laboratory, Bar Harbor, USA | 4 months | Molecular therapy, EB genetics, epigenetics & biology | Junctional | DEBRA Austria |
All Priorities Call 2010-01 | Dr Jakub Tolar | University of Minnesota, Departement of Pediatric Hermatology - Oncology / Blood and bone Marrow Transplantation, USA | 2 years | Molecular therapy | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2009-06 | Prof Mitchell Cairo | Columbia University, Departement of Medicine and Pathology, New York, USA | 1 year | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2009-06 | Dr Laurent Gagnoux-Palacios | A.D.S.M. Association pour le Développement des Sciences Médiacles, Faculté de Médicine, Nice, FRANCE | 3 years | Skin cancer & fibrosis | Junctional | DEBRA Austria |
All Priorities Call 2009-06 | Prof Josef Penninger | IMBA Institute of Molecular Biotechnology, Vienna, Austria | 2 years + 6 months | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2009-06 | Prof Colin Johada | Durham University, School of Biological and Biomedical Sciences, Durham, UK | 2 years | Cellular therapy | Dystrophic |
DEBRA Austria |
All Priorities Call 2009-06 | Dr John F. Marshall | Queen Mary University of London, Barts and London Medical School, Institute of Cancer, Centre for Tumour Biology, London, UK | 2 years | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2009-06 | Dr Andrew South | Ninewells Hospital and Medical School, Centre for Oncology and Molecular Medicine, Dundee, UK | 1 year | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
All Priorities Call 2009-06 | Dr Wensin Wang | NUIG National University of Ireland, Galway, Department of Mechanical and Biomedical Engineering, Galway, IRELAND | 1,5 years | Symptom prevention & relief | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2008-06 | Porf Johan Bauer | Division of Molecular Dermatology and EB House Austria, Paracelsus Private Medical University Salzburg, Austria | 3 years | Molecular therapy, Cellular therapy | Simplex | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2007 | Porf G Wiche | Max Perutz Laboratories, Vienna, Austria | 2 years | Molecular therapy | Simplex | DEBRA UK |
All Priorities Call 2007 | Prof Peter Marinkovich | Stanford University, California, USA | 1 year | Skin cancer & firbosis, Molecular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2007 | Dr Olga Igoucheva | Jefferson Medical College, Departement of Dermatology and Cutaneous Biology, hiladelphia, USA | 2 years | Cellular therapy | Dystrophic | DEBRA Austria |
